National Institutes of Health, a Component of the US Dept. of Health & Human Services

Jeffrey C Boyington

Masaru Kanekiyo

Barney S Graham

John R Mascola

Hadi M Yassine

Peter D Kwong

Yongping Yang

Michael Gordon Joyce

Ivelin Georgiev

Cheng Cheng

Baoshan Zhang

Gwo-Yu Chuang

Syed M Moin

Tongqing Zhou

Jason Scott McLellan

Guillaume Stewart-Jones

Yaroslav Tsybovsky

Marie Pancera

Man Chen

Gilad Ofek

Mallika Sastry

Jason Gorman

Cinque Soto

Lei Chen

Sanjay Srivatsan

Gary J Nabel

John Mascola

Aliaksandr Druz

Chih-Jen Wei

Lingshu Wang

Kizzmekia S Corbett

Ulrich Baxa

Joseph Van Galen

Xuejun Chen

Patrick M McTamney

Hongying Duan Holdsworth

Wing-Pui Kong

Li Ou

Kai Xu

Masaro Kanekiyo

Cara W Chao

Yiran Wang

Hui Geng

Yen-Ting Lai

Patrick M Mctamney

Md Nabel Gary J

Jason S Mclellan

Ivelin Stefanov Georgiev

Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

Stabilized influenza hemagglutinin stem region trimers and uses thereof

Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

Embodiments of immunogenic conjugates including the HIV-1 Env fusion peptide and methods of their use and production are disclosed. In several embodiments, the immunogenic conjugates can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Prefusion RSV F proteins and their use

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and methods of their use and production are disclosed. In several embodiments, the immunogen can be used to elicit an immune response to HIV-1 in a subject.

Recombinant HIV-1 envelope proteins and their use

Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens

Growing community of inventors

Clarksburg, MD, United States of America

Jeffrey C Boyington